Cidara Therapeutics Inc. | Mutual Funds
Mutual Funds that own Cidara Therapeutics Inc.
BB Biotech AG
2,295,272
8.28%
960,000
0.24%
03/31/2018
Fidelity Select Biotechnology Portfolio
1,204,886
4.34%
1,058,886
0.06%
07/31/2018
Vanguard Total Stock Market Index Fund
395,629
1.43%
0
0%
07/31/2018
Tekla Life Sciences Investors
286,472
1.03%
0
0.25%
12/31/2017
Fidelity Advisor Biotechnology Fund
258,767
0.94%
223,967
0.04%
07/31/2018
151,038
0.55%
0
0.32%
09/05/2018
Vanguard Extended Market Index Fund
139,986
0.51%
0
0%
07/31/2018
FCP OP Medical BioHe@lth-Trends
94,930
0.34%
0
0.23%
11/30/2017
Bridgeway Ultra Small Company Market Fund
94,000
0.34%
25,000
0.09%
12/31/2017
iShares Micro Cap ETF
48,100
0.17%
0
0.02%
09/06/2018
| Address |
6310 Nancy Ridge Drive
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.cidara.com |
| Updated |
07/08/2019 |
| Cidara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections. Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. |
